

Georgios Bakalos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8072970/publications.pdf>

Version: 2024-02-01

24
papers

340
citations

932766

10
h-index

839053

18
g-index

24
all docs

24
docs citations

24
times ranked

688
citing authors

#	ARTICLE	IF	CITATIONS
1	Advanced life support versus basic life support in the pre-hospital setting: A meta-analysis. Resuscitation, 2011, 82, 1130-1137.	1.3	70
2	A network meta-analysis of randomized controlled trials for comparing the effectiveness and safety profile of treatments with marketing authorization for relapsing multiple sclerosis. Journal of Clinical Pharmacy and Therapeutics, 2013, 38, 433-439.	0.7	31
3	Drug Discontinuation in Studies Including a Switch From an Originator to a Biosimilar Monoclonal Antibody: A Systematic Literature Review. Clinical Therapeutics, 2019, 41, 155-173.e13.	1.1	30
4	On-treatment prediction of sustained response to peginterferon alfa-2a for HBsAg-negative chronic hepatitis B patients. Liver International, 2015, 35, 1540-1548.	1.9	27
5	A baseline tool for predicting response to peginterferon alfa-2a in HBsAg-positive patients with chronic hepatitis B. Alimentary Pharmacology and Therapeutics, 2018, 48, 547-555.	1.9	27
6	Evidence of Association Between Methylene tetrahydrofolate Reductase Gene and Susceptibility to Breast Cancer: A Candidate-Gene Association Study in a South-Eastern European Population. DNA and Cell Biology, 2012, 31, 193-198.	0.9	23
7	Monoclonal Antibody Biosimilars in Oncology: Critical Appraisal of Available Data on Switching. Clinical Therapeutics, 2018, 40, 798-809.e2.	1.1	21
8	Variants of the MTHFR gene and susceptibility to acute lymphoblastic leukemia in children: A synthesis of genetic association studies. Cancer Epidemiology, 2012, 36, 169-176.	0.8	20
9	Comparative immunogenicity assessment of biosimilars. Future Oncology, 2019, 15, 319-329.	1.1	18
10	IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational Gen-C study. SpringerPlus, 2016, 5, 1990.	1.2	11
11	Assessing the relative effectiveness and tolerability of treatments in small cell lung cancer: A network meta-analysis. Cancer Epidemiology, 2013, 37, 675-682.	0.8	8
12	Responses are durable for up to 5 years after completion of peginterferon alfa-2a treatment in hepatitis B e antigen-positive patients. Alimentary Pharmacology and Therapeutics, 2018, 47, 1306-1316.	1.9	8
13	Extended treatment with pegylated interferon alfa/ribavirin in patients with genotype 2/3 chronic hepatitis C who do not achieve a rapid virological response: final analysis of the randomised N-CORE trial. Hepatology International, 2014, 8, 517-526.	1.9	6
14	An easy-to-use baseline scoring system to predict response to peginterferon alfa-2a in patients with chronic hepatitis B in resource-limited settings. Antiviral Therapy, 2018, 23, 655-663.	0.6	6
15	Development pathways for subcutaneous formulations of biologics versus biosimilar development. Expert Review of Precision Medicine and Drug Development, 2022, 7, 62-69.	0.4	6
16	Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study. Annals of Gastroenterology, 2017, 30, 327-343.	0.4	6
17	Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort. PLoS ONE, 2016, 11, e0151703.	1.1	5
18	A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin. PLoS ONE, 2016, 11, e0150569.	1.1	4

#	ARTICLE	IF	CITATIONS
19	A genotype-specific baseline score predicts post-treatment response to peginterferon alfa-2a in Hepatitis B e antigen-negative chronic hepatitis B. <i>Annals of Gastroenterology</i> , 2018, 31, 712-721.	0.4	4
20	Reply to "Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers". <i>ESMO Open</i> , 2017, 2, e000281.	2.0	3
21	Simple Predictive Model for Identifying Patients with Chronic Hepatitis C and Hepatitis C Virus Genotype 4 Infection with a High Probability of Sustained Virologic Response with Peginterferon Alfa-2a/Ribavirin: Pooled Analysis of Data from Two Large, International Cohort Studies. <i>Advances in Therapy</i> , 2016, 33, 1797-1813.	1.3	2
22	Boceprevir Plus Peginterferon Alfa-2a/Ribavirin in Treatment-Naïve Hepatitis C Virus Genotype 1 Patients: International Phase IIIb/IV TriCo Trial. <i>Infectious Diseases and Therapy</i> , 2016, 5, 113-124.	1.8	2
23	Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B. <i>PLoS ONE</i> , 2020, 15, e0230893.	1.1	2
24	Reply letter to: Do we really need more research in order to be convinced that advanced life support is superior to basic life support for the non traumatic cardiac arrest patients?. <i>Resuscitation</i> , 2011, 82, e9-e10.	1.3	0